Total: $65.7M

Year to Date: $362.53M

Company (Location)

Partner (Location)

Amt.(M)

Details (Date)

Affymax Inc. (Palo Alto, Calif.)

Takeda Pharmaceutical Co. Ltd. (Osaka, Japan)

$10

For the acceptance and filing of a new drug application for peginesatide by the FDA (8/11)

Ariad Pharmaceuticals Inc. (Cambridge, Mass.)

Merck and Co. Inc. (Whitehouse Station, N.J.)

$25

For the European Medicines Agency's acceptance for review of the MAA for ridaforolimus in metastatic soft-tissue or bone sarcomas (8/19)

Evotec AG (Hamburg, Germany)

Boehringer Ingelheim GmbH (Ingelheim, Germany)

€4 ($5.7)

For the identification and selection of a compound to advance into preclinical development within an oncology program (8/19)

MAP Pharmaceuticals Inc. (Moutain View, Calif.)

Allergan Inc. (Irvine, Calif.)

$20

For the FDA's acceptance of an NDA for Levadex, an orally inhaled migraine drug (8/3)

Nabi Biopharma-ceuticals Inc. (Rockville, Md.)

Fresenius USA Manufacturing Inc. (Walnut Creek, Calif.)

$5

For the first commercial sale of Phoslyra (8/17)

Notes:

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ND = Not disclosed. ** Denotes the date the item ran in BioWorld International.